🇺🇸 FDA
Pipeline program

LANSOPRAZOLE, LANSOPRAZOLE, Placebo to match lansoprazole high dose, Linaprazan glurate, Placebo to match Lansoprazole low dose, Placebo to match Linaprazan Glurate

CX842A2303

Phase 3 small_molecule active

Quick answer

LANSOPRAZOLE, LANSOPRAZOLE, Placebo to match lansoprazole high dose, Linaprazan glurate, Placebo to match Lansoprazole low dose, Placebo to match Linaprazan Glurate for Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials